PriceTargets.com logo

Tyra Biosciences - TYRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 31.66%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$15.95 As of 03/24/2023 01:00 AM ET
▲ +0.5 (3.24%)

This chart shows the closing price for TYRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tyra Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TYRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TYRA

Analyst Price Target is $21.00
▲ +31.66% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tyra Biosciences in the last 3 months. The average price target is $21.00, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 31.66% upside from the last price of $15.95.

This chart shows the closing price for TYRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Tyra Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2023HC WainwrightReiterated RatingBuy$17.00Low
3/2/2023HC WainwrightBoost TargetBuy$12.00 ➝ $15.00Low
3/1/2023OppenheimerBoost Target$17.00 ➝ $25.00Low
2/2/2023OppenheimerInitiated CoverageOutperform$17.00Low
6/23/2022HC WainwrightInitiated CoverageBuy$12.00Low
3/8/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00 ➝ $27.00High
11/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$19.00 ➝ $31.00Low
10/11/2021Bank of AmericaInitiated CoverageBuy$22.00High
10/11/2021Jefferies Financial GroupInitiated CoverageBuy$19.00High
10/11/2021CowenInitiated CoverageOutperformHigh
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tyra Biosciences logo
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Read More

Today's Range

Now: $15.95
Low: $14.73
High: $16.00

50 Day Range

MA: $12.27
Low: $7.73
High: $15.97

52 Week Range

Now: $15.95
Low: $4.93
High: $16.00

Volume

29,178 shs

Average Volume

56,459 shs

Market Capitalization

$676.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Tyra Biosciences?

The following equities research analysts have issued research reports on Tyra Biosciences in the last year: HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TYRA.

What is the current price target for Tyra Biosciences?

2 Wall Street analysts have set twelve-month price targets for Tyra Biosciences in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 31.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting TYRA will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Tyra Biosciences in the next year.
View the latest price targets for TYRA.

What is the current consensus analyst rating for Tyra Biosciences?

Tyra Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TYRA will outperform the market and that investors should add to their positions of Tyra Biosciences.
View the latest ratings for TYRA.

What other companies compete with Tyra Biosciences?

Other companies that are similar to Tyra Biosciences include Theravance Biopharma, Dyne Therapeutics, Amarin, Arcutis Biotherapeutics and RAPT Therapeutics. Learn More about companies similar to Tyra Biosciences.

How do I contact Tyra Biosciences' investor relations team?

Tyra Biosciences' physical mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The company's listed phone number is 619-728-4760 and its investor relations email address is [email protected] The official website for Tyra Biosciences is www.tyra.bio. Learn More about contacing Tyra Biosciences investor relations.